---
pmid: '27238082'
title: Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF
  Inhibitor Resistance.
authors:
- Cerezo M
- Lehraiki A
- Millet A
- Rouaud F
- Plaisant M
- Jaune E
- Botton T
- Ronco C
- Abbe P
- Amdouni H
- Passeron T
- Hofman V
- Mograbi B
- Dabert-Gay AS
- Debayle D
- Alcor D
- Rabhi N
- Annicotte JS
- Héliot L
- Gonzalez-Pisfil M
- Robert C
- Moréra S
- Vigouroux A
- Gual P
- Ali MMU
- Bertolotto C
- Hofman P
- Ballotti R
- Benhida R
- Rocchi S
journal: Cancer Cell
year: '2016'
full_text_available: false
doi: 10.1016/j.ccell.2016.04.013
---

# Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance.
**Authors:** Cerezo M, Lehraiki A, Millet A, Rouaud F, Plaisant M, Jaune E, Botton T, Ronco C, Abbe P, Amdouni H, Passeron T, Hofman V, Mograbi B, Dabert-Gay AS, Debayle D, Alcor D, Rabhi N, Annicotte JS, Héliot L, Gonzalez-Pisfil M, Robert C, Moréra S, Vigouroux A, Gual P, Ali MMU, Bertolotto C, Hofman P, Ballotti R, Benhida R, Rocchi S
**Journal:** Cancer Cell (2016)
**DOI:** [10.1016/j.ccell.2016.04.013](https://doi.org/10.1016/j.ccell.2016.04.013)

## Abstract

1. Cancer Cell. 2016 Jun 13;29(6):805-819. doi: 10.1016/j.ccell.2016.04.013. Epub
 2016 May 26.

Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF 
Inhibitor Resistance.

Cerezo M(1), Lehraiki A(1), Millet A(2), Rouaud F(1), Plaisant M(1), Jaune E(1), 
Botton T(1), Ronco C(2), Abbe P(1), Amdouni H(2), Passeron T(3), Hofman V(4), 
Mograbi B(5), Dabert-Gay AS(6), Debayle D(6), Alcor D(1), Rabhi N(7), Annicotte 
JS(7), Héliot L(8), Gonzalez-Pisfil M(8), Robert C(9), Moréra S(10), Vigouroux 
A(10), Gual P(11), Ali MMU(12), Bertolotto C(3), Hofman P(4), Ballotti R(3), 
Benhida R(13), Rocchi S(14).

Author information:
(1)INSERM, U1065, Equipe Biologie et Pathologie des cellules mélanocytaire: de 
la pigmentation cutanée au mélanome, Centre Méditerranéen de Médecine 
Moléculaire (C3M), Bâtiment ARCHIMED, 151 route de Saint Antoine de Ginestière, 
06204 Nice cedex 3, France; UFR de Médecine, Université de Nice Sophia 
Antipolis, 06000 Nice, France.
(2)Institut de Chimie de Nice UMR UNS-CNRS 7272, Université Nice Sophia 
Antipolis, Parc Valrose, 06108 Nice cedex 2, France.
(3)INSERM, U1065, Equipe Biologie et Pathologie des cellules mélanocytaire: de 
la pigmentation cutanée au mélanome, Centre Méditerranéen de Médecine 
Moléculaire (C3M), Bâtiment ARCHIMED, 151 route de Saint Antoine de Ginestière, 
06204 Nice cedex 3, France; UFR de Médecine, Université de Nice Sophia 
Antipolis, 06000 Nice, France; Service de Dermatologie, Hôpital Archet II, CHU, 
06204 Nice, France.
(4)UFR de Médecine, Université de Nice Sophia Antipolis, 06000 Nice, France; 
Institute of Research on Cancer and Ageing of Nice (IRCAN), INSERM U1081, CNRS 
UMR7284, Nice 06107, France; Laboratoire de pathologie clinique et expérimentale 
et Hospital-related biobank (BB-0033-00025), Hôpital Pasteur, 06002 Nice, 
France.
(5)UFR de Médecine, Université de Nice Sophia Antipolis, 06000 Nice, France; 
Institute of Research on Cancer and Ageing of Nice (IRCAN), INSERM U1081, CNRS 
UMR7284, Nice 06107, France.
(6)UFR de Médecine, Université de Nice Sophia Antipolis, 06000 Nice, France; 
CNRS UMR 7275, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), 06560 
Sophia Antipolis, France.
(7)University Lille, CNRS, Institut Pasteur de Lille, UMR 8199 - EGID, 59000 
Lille, France.
(8)Equipe Biophotonique Cellulaire Fonctionnelle, Laboratoire de Physique des 
Lasers, Atomes et Molécules (PhLAM) GDR 2588, 59658 Villeneuve d'Ascq, France.
(9)Department of Dermatology, Cancer Campus, Gustave Roussy Institute, 114, rue 
Edouard-Vaillant, 94805 Villejuif, France.
(10)Institute for Integrative Biology of the Cell (I2BC), CNRS CEA University 
Paris-Sud, Université Paris-Saclay, Gif-sur-Yvette 91198, France.
(11)INSERM, U1065, Team 8, Centre Méditerranéen de Médecine Moléculaire (C3M), 
151 route de Saint Antoine de Ginestière, 06204 Nice cedex 3, France.
(12)Department of Life Sciences, Imperial College London, South Kensington 
Campus, London SW7 2AZ, UK.
(13)Institut de Chimie de Nice UMR UNS-CNRS 7272, Université Nice Sophia 
Antipolis, Parc Valrose, 06108 Nice cedex 2, France. Electronic address: 
benhida@unice.fr.
(14)INSERM, U1065, Equipe Biologie et Pathologie des cellules mélanocytaire: de 
la pigmentation cutanée au mélanome, Centre Méditerranéen de Médecine 
Moléculaire (C3M), Bâtiment ARCHIMED, 151 route de Saint Antoine de Ginestière, 
06204 Nice cedex 3, France; UFR de Médecine, Université de Nice Sophia 
Antipolis, 06000 Nice, France; Service de Dermatologie, Hôpital Archet II, CHU, 
06204 Nice, France. Electronic address: srocchi@unice.fr.

Erratum in
    Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.007.

Comment in
    Cancer Cell. 2016 Jun 13;29(6):769-771. doi: 10.1016/j.ccell.2016.05.006.
    Pigment Cell Melanoma Res. 2016 Sep;29(5):490-1. doi: 10.1111/pcmr.12499.

We have discovered and developed a series of molecules (thiazole 
benzenesulfonamides). HA15, the lead compound of this series, displayed 
anti-cancerous activity on all melanoma cells tested, including cells isolated 
from patients and cells that developed resistance to BRAF inhibitors. Our 
molecule displayed activity against other liquid and solid tumors. HA15 also 
exhibited strong efficacy in xenograft mouse models with melanoma cells either 
sensitive or resistant to BRAF inhibitors. Transcriptomic, proteomic, and 
biochemical studies identified the chaperone BiP/GRP78/HSPA5 as the specific 
target of HA15 and demonstrated that the interaction increases ER stress, 
leading to melanoma cell death by concomitant induction of autophagic and 
apoptotic mechanisms.

Copyright © 2016 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccell.2016.04.013
PMID: 27238082 [Indexed for MEDLINE]
